Gaithersburg, MD, September 22, 2015  – MaxCyte®, Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, will present new data that is the result of a collaboration with Christian-Albrechts-University in Kiel, Germany at the 6th World Bispecific Antibody Summit on September 23, 2015, in Boston, MA. Data will be shared in a podium presentation by Dr. James Brady showing how flow electroporation technology can produce biologically active bispecific antibodies via transient expression in CHO cells. Specifically, the data will examine the expression, binding, and cytotoxicity of bispecific antibodies and tribodies transiently produced that specifically recruit immune effector cells to cancer cells.


Details of the MaxCyte presentation are as follows:

Event: 6th World Bispecific Antibody Summit

Title: Rapid, Scalable Expression of Bispecific Drugs In CHO Cells

Date: Wednesday, September 23, 2015

Time: 4:00 PM

Location: The Joseph B. Martin Conference Center, Boston, MA


Along with the podium presentation, MaxCyte will present a scientific poster with the new data and have an exhibit booth with the MaxCyte STX® Scalable Transfection System. MaxCyte scientists will be available throughout the conference to provide technical details.


About MaxCyte

MaxCyte is the leader in driving the next generation of cell-based medicines. MaxCyte’s cell modification technology, flow electroporation, is used for discovery, development, and manufacture of small molecule, biologic, and cell-based therapeutics. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of transfected cells for a broad array of applications.

For more information visit /